The role of GLP-1 agonists with a strategy of its receptor (GLP-1R) activation or sustained levels of increased GLP-1 has been established as a potential therapeutic strategy for weight management and obesity-associated type-2 diabetes (54–56). This evidence concerns the gene GCG and type 2 diabetes mellitus.